Astragalus membranaceus inhibits inflammation via phospho-p38 mitogen-activated protein kinase (MAPK) and nuclear factor (NF)-κB pathways in advanced glycation end product-stimulated macrophages

International Journal of Molecular Sciences

Volumn 13, Issue 7, 2012, Pages 8379-8387

  Qin, Qiaojing ^a   Niu, Jianying ^a   Wang, Zhaoxia ^b   Xu, Wangjie ^b   Qiao, Zhongdong ^b   Gu, Yong ^a,c  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Advanced glycation end products; Astragalus membranaceus; Diabetes; Inflammation; Macrophage

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ASTRAGALUS MEMBRANACEUS EXTRACT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; PLANT EXTRACT;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; IMMUNOREGULATION; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; ASTRAGALUS MEMBRANACEUS; CELL CULTURE; CELL SURVIVAL; CHEMISTRY; DIABETES MELLITUS; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SECRETION (PROCESS); SIGNAL TRANSDUCTION;

ASTRAGALUS MEMBRANACEUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ASTRAGALUS MEMBRANACEUS; CELL SURVIVAL; CELLS, CULTURED; DIABETES MELLITUS; DRUG EVALUATION, PRECLINICAL; GLYCOSYLATION END PRODUCTS, ADVANCED; INTERLEUKIN-1BETA; MACROPHAGES; MAP KINASE SIGNALING SYSTEM; MICE; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PLANT EXTRACTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864338462     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13078379     Document Type: Article

References (25)

1. Donath, M.Y. Inflammation as a sensor of metabolic stress in obesity and type 2 diabetes. Endocrinology 2011, 152, 4005-4006.
2. Darisipudi, M.N.; Kulkarni, O.P.; Sayyed, S.G.; Ryu, M.; Migliorini, A.; Sagrinati, C. Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease. Am. J. Pathol. 2011, 179, 116-124.
3. Tesch, G.H. Macrophages and diabetic nephropathy. Semin. Nephrol. 2010, 30, 290-301.
4. Nogi, Y.; Nagashima, M.; Terasaki, M.; Nohtomi, K.; Watanabe, T.; Hirano, T. Glucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein e-null mice. PLoS One 2012, 7, e35683.
5. Qiao, M.; Zhao, Q.; Lee, C.F.; Tannock, L.R.; Smart, E.J.; LeBaron, R.G.; Phelix, C.F.; Rangel, Y.; Asmis, R. Thiol oxidative stress induced by metabolic disorders amplifies macrophage chemotactic responses and accelerates atherogenesis and kidney injury in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 1779-1786.
6. Ninichuk, V.; Khandoga, A.G.; Segerer, S.; Loetscher, P.; Schlapbach, A.; Revesz, L.; Feifel, R.; Khandoga, A.; Krombach, F.; Nelson, P.J.; et al. The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice. Am. J. Pathol. 2007, 170, 1267-1276.
7. Usui, H.K.; Shikata, K.; Sasaki, M.; Okada, S.; Matsuda, M.; Shikata, Y. Macrophage scavenger receptor-A-deficient mice are resistant against diabetic nephropathy through amelioration of microinflammation. Diabetes 2007, 56, 363-372.
8. Reddy, M.A.; Natarajan, R. Epigenetic mechanisms in diabetic vascular complications. Cardiovasc. Res. 2011, 90, 421-429.
9. Bao, W.; Min, D.; Twigg, S.M.; Shackel, N.A.; Warner, F.J.; Yue, D.K. Monocyte CD147 is induced by advanced glycation end products and high glucose concentration: Possible role in diabetic complications. Am. J. Physiol. Cell Physiol. 2010, 299, C1212-C1219.
10. Kaushansky, K.; Broudy, V.C.; Harlan, J.M.; Adamson, J.W. Tumor necrosis factor-alpha and tumor necrosis factor-β (lymphotoxin) stimulate the production of granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and IL-1 in vivo. J. Immunol. 1988, 141, 3410-3415.
11. Dinarello, C.A. A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur. J. Immunol. 2011, 41, 1203-1217.
12. Saitoh, T.; Fujita, N.; Jang, M.H.; Uematsu, S.; Yang, B.G.; Satoh, T. Loss of the autophagy protein Atg16 L1 enhances endotoxin-induced IL-1β production. Nature 2008, 456, 264-268.
13. Ibrahim, A.S.; El-Remessy, A.B.; Matragoon, S.; Zhang, W.; Patel, Y.; Khan, S. Retinal microglial activation and inflammation induced by amadori-glycated albumin in a rat model of diabetes. Diabetes 2011, 60, 1122-1133.
14. Chen, H.Y.; Huang, X.R.; Wang, W.; Li, J.H.; Heuchel, R.L.; Chung, A.C. The protective role of Smad7 in diabetic kidney disease: Mechanism and therapeutic potential. Diabetes 2011, 60, 590-601.
15. Ko, J.K.; Chik, C.W. The protective action of radix Astragalus membranaceus against hapten-induced colitis through modulation of cytokines. Cytokine 2009, 47, 85-90.
16. Zong, H.; Ward, M.; Madden, A.; Yong, P.H.; Limb, G.A.; Curtis, T.M. Hyperglycaemia-induced pro-inflammatory responses by retinal Müller glia are regulated by the receptor for advanced glycation end-products (RAGE). Diabetologia 2010, 53, 2656-2666.
17. Nin, J.W.; Jorsal, A.; Ferreira, I.; Schalkwijk, C.G.; Prins, M.H.; Parving, H.H. Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: A 12-year follow-up study. Diabetes 2010, 59, 2027-2032.
18. Aouadi, M.; Tesz, G.J.; Nicoloro, S.M.; Wang, M.; Chouinard, M.; Soto, E. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 2009, 458, 1180-1184.
19. Sartippour, M.R.; Renier, G. Upregulation of macrophage lipoprotein lipase in patients with type 2 diabetes: Role of peripheral factors. Diabetes 2000, 49, 597-602.
20. Zhao, L.H.; Ma, Z.X.; Zhu, J.; Yu, X.H.; Weng, D.P. Characterization of polysaccharide from Astragalus radix as the macrophage stimulator. Cell. Immunol. 2011, 271, 329-334.
21. Van Zoelen, M.A.; Schouten, M.; de Vos, A.F.; Florquin, S.; Meijers, J.C.; Nawroth, P.P. The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia. J. Immunol. 2009, 182, 4349-4356.
22. Li, Y.; Reddy, M.A.; Miao, F.; Shanmugam, N.; Yee, J.K.; Hawkins, D. Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-kappaB-dependent inflammatory genes. J. Biol. Chem. 2008, 283, 26771-26781.
23. Dean, J.L.; Brook, M.; Clark, A.R.; Saklatvala, J. p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharidetreated human monocytes. J. Biol. Chem. 1999, 274, 264-269.
24. Zhang, F.; Banker, G.; Liu, X.; Suwanabol, P.A.; Lengfeld, J.; Yamanouchi, D. The Novel Function of Advanced Glycation End Products in Regulation of MMP-9 Production. J. Surg. Res. 2011, 171, 871-876.
25. Weidenbusch, M.; Anders, H.J. Tissue microenvironments define and get reinforced by macrophage phenotypes in homeostasis or during inflammation, repair and fibrosis. J. Innate Immun. 2012, doi:10.1159/000336717.